Table 1: Glucose transporter expression in ovarian and other cancers.

Facilitative Transporters: Class 1 GLUTs

Major site of expressionExpression in EOC [7780]Localization in EOC [7780] Expression in other cancers
GLUT-1Fetal tissue, erythrocytes; widely distributedOverexpressed in almost all invasive carcinomas; expression increases from benign to invasive tumoursCell membrane, cytoplasm; more in membrane in more invasive; some studies say stronger closer to periphery; some say farther from tumour-stromal interfaceBreast [82, 83], head, and neck [84], colorectal [85], prostate [86], pancreatic [87], cervical [88]
GLUT-2Liver, pancreasNegativeUnknownIslet cell tumours [89], sarcoma [90]
GLUT-3BrainConflicting: reported to be high in >90% of EOC tumours; also weak, homogenous expression in all ovarian tissue; also in ovarian tumours but not normal tissueCytoplasm and cell membraneLymphoma [91], head and neck [92], lung [93]
GLUT-4Insulin-responsive tissues (skeletal muscle, heart, adipose tissue)Conflicting: no expression in normal or malignant; also present in up to 84% in ovarian tumour cellsUnknownLung [94], breast [95]

Active Transporters: SGLTs.

Major site of expressionExpression in EOCLocalization in EOC Expression in other cancers
SGLT1Kidney and small intestineNot investigatedUnknownBreast [96], prostate [96], head and neck [97], pancreatic [98]
SGLT2Kidney and small intestineNot investigatedUnknownNo reports
SGLT3Skeletal muscle and small intestineNot investigatedUnknownNo reports